The importance of measuring IFNβ bioactivity: Monitoring in MS patients and the effect of anti-IFNβ antibodies

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.

1993 • 1,227 citations

PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS

2001 • 563 citations

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS

2001 • 471 citations

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

2003 • 370 citations

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis

1998 • 332 citations

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies

1999 • 194 citations

Mini ReviewHuman Interferons Alpha, Beta and Omega

2004 • 191 citations

Complex immunomodulatory effects of interferon‐β in multiple sclerosis include the upregulation of T helper 1‐associated marker genes

2001 • 179 citations

Persistent neutralizing antibodies abolish the interferon β bioavailability in MS patients

2003 • 173 citations

Neutralizing antibodies reduce the efficacy of βIFN during treatment of multiple sclerosis

2004 • 153 citations

A Novel Bioassay for the Determination of Neutralizing Antibodies to IFNβ1b

1998 • 100 citations

Comparative Study of the Pharmacodynamic and Pharmacologic Effects of Betaseron^®and AVONEX^™

1998 • 92 citations

Evaluation of bioavailability of three types of IFNβ in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification

2001 • 88 citations

MxA Gene Expression Analysis as an Interferon-β Bioactivity Measurement in Patients with Multiple Sclerosis and the Identification of Antibody-Mediated Decreased Bioactivity

2003 • 88 citations

A comparative study of the relative bioavailability of different interferon beta preparations

2000 • 86 citations

Pharmacodynamic Comparison of Single Doses of IFN-beta 1a and IFN-beta 1b in Healthy Volunteers

1999 • 81 citations

Neutralizing antibodies reduce MxA protein induction in interferon- beta-1a-treated MS patients

2002 • 78 citations

Microarray analysis identifies interferon β-regulated genes in multiple sclerosis

2003 • 76 citations

Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis

2004 • 72 citations

Measurement of MxA mRNA or protein as a biomarker of IFNβ bioactivity

2003 • 72 citations

Multiple Sclerosis: Levels of Interleukin‐10‐Secreting Blood Mononuclear Cells are Low in Untreated Patients but Augmented During Interferon‐β‐1b Treatment

1999 • 71 citations

Neutralizing antibodies against IFN- in multiple sclerosis: antagonization of IFN- mediated suppression of MMPs

2004 • 68 citations

Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients

2001 • 62 citations

ELISA methods for the analysis of antibody responses induced in multiple sclerosis patients treated with recombinant interferon-β

1999 • 60 citations

Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies

2004 • 57 citations

Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis

2004 • 55 citations

An improved ELISA for screening for neutralizing anti-IFN-β antibodies in MS patients

2003 • 53 citations

Anti-IFN BAb and NAb antibodies

2003 • 49 citations

Identification of Critical Residues in Bovine IFNAR-1 Responsible for Interferon Binding

2001 • 32 citations

MRI and clinical activity in MS patients after terminating treatment with interferon beta-l b

2000 • 30 citations

Characterization of a soluble ternary complex formed between human interferon‐β‐1a and its receptor chains

1999 • 27 citations

Anti-IFNβ antibodies in IFNβ-treated MS patients

2003 • 26 citations

MxA Gene Expression Analysis as an Interferon-?? Bioactivity Measurement in Patients with Multiple Sclerosis and the Identification of Antibody-Mediated Decreased Bioactivity

2003 • 25 citations

Evaluation of IFNα bioavailability by MxA mRNA in HCV patients

2002 • 20 citations

Is serum neopterin level a marker of responsiveness to interferon beta-1a therapy in multiple sclerosis?

2004 • 13 citations

Cited By (0)

Loading...